'Potential Link Between Ozempic, Wegovy And Serious Eye Condition Revealed In New Study' - New York Post
'Potential Link Between Ozempic, Wegovy And Serious Eye Condition Revealed In New Study' - New York Post
Researchers say they have uncovered a link between semaglutide — the active ingredient in Ozempic and Wegovy — and sudden vision loss.
研究人員稱他們已經發現了Ozempic和Wegovy中的活性成分semaglutide與突發視力喪失之間的聯繫。
The risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) is four times higher for diabetics on semaglutide and seven times higher for people taking the drug to lose weight, according to a new study from Massachusetts Eye and Ear, a teaching hospital of Harvard Medical School.
根據哈佛醫學院的附屬醫院，馬薩諸塞州眼耳科，一項新研究顯示糖尿病患者在服用semaglutide藥物的非動脈前緣性缺血性視神經病變（NAION）風險增加了4倍，而服用該藥減肥的人的風險增加了7倍。
A relatively rare condition, NAION is believed to be caused by insufficient blood flow to the optic nerve head. The result is painless but irreversible vision loss in one eye. There are no effective treatments for NAION.
NAION是一種相對罕見的疾病，據信是由於視神經頭血液供應不足引起的。其結果是一個眼睛無痛但不可逆轉的視力損失。目前還沒有對NAION的有效治療方法。
NAION is not fully understood — and neither is the purported relationship between semaglutide and the optic nerve disorder.
NAION並沒有被完全理解，semaglutide與視神經障礙之間的關係也是如此。
"This study is the first, to our knowledge, to report an association between semaglutide and NAION, although the design of our study did not enable query into a causal relationship between the two," the researchers wrote in their findings, published Wednesday in the journal JAMA Ophthalmology.
研究人員在他們的研究中寫道：“雖然我們的研究設計不能查詢兩者之間的因果關係，但這項研究是我們所知道的第一個報道semaglutide和NAION之間關聯的研究。”這項研究結果於週三發表在《JAMA眼科》雜誌上。
譯文內容由第三人軟體翻譯。